ESTRO 2024 - Abstract Book

S2280

Clinical - Upper GI

ESTRO 2024

Conclusion:

SABR is a well-tolerated and effective treatment prior to LT, providing a pathological response rate of 85.4%, even though 23.2% of explanted livers ultimately contained viable tumors undetected by pre-LT restaging imaging. mRECIST is a poor approximate of pathological response grading criteria. Since the effect of SABR on surgical complications is almost unknown, our future efforts will focus on identifying potential associations between SABR parameters and transplant complications.

Keywords: SABR, HCC, Liver Transplantation

References:

1. Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol Biol Phys (2012) 83:895 – 900. doi: 10.1016/j.ijrobp.2011.08.032 2. Mohamed M, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, Qiu H, Hezel AF, Ramaraju GA, Dokus MK, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol (2016) 1:35 – 42. doi: 10.1016/j.adro.2015.12.003 3. Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, Issachar A, Mor E, Sarfaty M, Bragilovski D, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiat Oncol (2017) 12:163. doi: 10.1186/s13014-017-0899-4